BioWorld MedTech

Jan. 12, 2015

InVivo reopens enrollment for Neuro-Spinal Scaffold

InVivo Therapeutics (Cambridge, Massachusetts) reported the reopening of subject enrollment for the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Read More

It's Complicated: Genome studies broaden and deepen as methods progress

FDA grants CLIA waiver for molecular diagnostic test for influenza A & B

Inside the Beltway: Palmetto's Putcha: FDA oversight of LDTs could push testing to clinics

Attached to today's issue: The MDD 4Q Report.

Financings: PureTech closes on $50 million growth stage investment round

Report from Europe; Mauna Kea reports its sales are up 10% despite 'sharply contrasting trends'

HIT Bits: Mirth to power patient health information for Arizona network

MDD's Stock Market Winners and Losers

MDD's Stock Report for the week of 1/2-1/9

Briefly noted

People in Places

Product briefs

MDD's Neurology Extra

MDD's 4Q Report: Mergers and Acquisitions: Fewer, but more valuable, deals are the trend for last quarter of 2014

4Q14 Deals Chart

MDD's 4Q Report: Financings: Series A funding and IPOs show steady resolve in 4Q14

4Q14 Financial Chart

MDD's 4Q Report: Inside the Beltway FDA publishes revised draft guidance for LDT regulation

MDD's 4Q Report: Agreements/contracts: End of year slows down a bit, but still sees quality partnerships

Today's news in brief

BioWorld

BioWorld briefs for Dec. 19, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 19, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...